Robert Coleman
Expertise in
2
conditions

Dr. Robert Coleman

General Surgery
Mayor Heart & Lung Surgery Of Kansas LLC
8901 W 74th St Ste 1, 
Overland Park, KS 
Expertise in
2
conditions
Mayor Heart & Lung Surgery Of Kansas LLC
8901 W 74th St Ste 1, 
Overland Park, KS 

Overview

Robert Coleman is a General Surgeon practicing medicine in Overland Park, Kansas.

Dr. Coleman is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Fractured Spine, PIK3CA-Related Overgrowth Spectrum, Menopause, Lymphadenectomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 425 peer reviewed articles and participating in 17 clinical trials.

Specialties

General Surgery

Licenses

Plastic Surgery in KS

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO

Locations

Mayor Heart & Lung Surgery of Kansas LLC
8901 W 74th St Ste 1, Overland Park, KS 66204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition
EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2026
Intervention Type: Drug
Study Drugs: Adavosertib, Olaparib
Study Phase: Phase 2
EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery: A Phase I Clinical Trial
EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery: A Phase I Clinical Trial
Enrollment Status: Active_not_recruiting
Publish Date: January 07, 2026
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: November 13, 2025
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Enrollment Status: Completed
Publish Date: June 08, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 2
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: Bevacizumab, Emactuzumab, Paclitaxel
Study Phase: Phase 2
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
Enrollment Status: Unknown
Publish Date: January 25, 2022
Intervention Type: Biological, Drug, Other
Study Drugs: Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide Phosphate, Paclitaxel
Study Phase: Phase 2
View 8 Less Clinical Trials

425 Total Publications

Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].
Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].
Journal: Gynecologic oncology
Published: June 02, 2026
Similar Doctors
Expertise in
10
conditions
Dr. David Juang
General Surgery
Expertise in
10
conditions
Dr. David Juang
General Surgery
Referral may be required

Pediatric Surgical Specialists - Overland Park

12200 W 106th St Ste 210, 
Overland Park, KS 
 (6.7 miles away)
Languages Spoken:
English
See accepted insurances

David Juang is a General Surgeon practicing medicine in Overland Park, Kansas. Dr. Juang is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Infantile Pneumothorax, Infantile Pyloric Stenosis, Atresia of Small Intestine, Gastrostomy, and Appendectomy.

Expertise in
9
conditions
Dr. Christa R. Balanoff
General Surgery
Expertise in
9
conditions
Dr. Christa R. Balanoff
General Surgery
Referral may be required

KU MedWest

7405 Renner Road, 
Shawnee, KS 
 (7.9 miles away)
913-588-1227
Experience:
30+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christa Balanoff is a General Surgeon practicing medicine in Shawnee, Kansas. She has been practicing medicine for over 30 years. Dr. Balanoff is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Angiosarcoma, Paget Disease of the Breast, Intraductal Papilloma, and Mastectomy. Dr. Balanoff is board certified in American Board Of Surgery, Surgery (General Surgery) - 2003. Dr. Balanoff is currently accepting new patients.

Expertise in
18
conditions
Dr. Austin Lehr
General Surgery
Expertise in
18
conditions
Dr. Austin Lehr
General Surgery
Referral may be required

Kansas City Vascular And General Surgery - Overland Park

5100 W 110th St Ste 300, 
Overland Park, KS 
 (4.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Austin Lehr is a General Surgeon practicing medicine in Overland Park, Kansas. Dr. Lehr is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Cholecystitis, Gallbladder Disease, Ogilvie Syndrome, Hernia Surgery, and Small Bowel Resection. Dr. Lehr is currently accepting new patients.

Frequently Asked Questions about Dr. Robert Coleman

How do I make an appointment with Dr. Robert Coleman?

You can book an appointment with Dr. Robert Coleman by calling their office at 913-362-0100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert Coleman a top-rated expert for Fractured Spine?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert Coleman is classified as an Advanced expert for Fractured Spine, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert Coleman specialize in?

While Dr. Robert Coleman is a General Surgery, they have specific expertise in Fractured Spine, PIK3CA-Related Overgrowth Spectrum, and Lymphadenectomy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within General Surgery.

Does Dr. Robert Coleman participate in research or clinical trials?

Yes. Dr. Robert Coleman has published 425 articles and abstracts on conditions like Fractured Spine. You can view a list of Dr. Robert Coleman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Robert Coleman accept my insurance?

Dr. Robert Coleman accepts most major insurance plans, including Aetna. We recommend calling the office directly at 913-362-0100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Coleman's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile